Brainshuttle AD: A Phase Ib/IIa Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6102 in Participants with Prodromal or Mild-to-moderate Alzheimer’s Disease

RG6102 is a monoclonal antibody under development for the treatment of Alzheimer’s disease. It combines the anti-beta-amyloid antibody gantenerumab with a “Brain Shuttle” module that binds to the transferrin receptor 1, facilitating receptor-mediated transport across the blood-brain barrier. This presentation presents the study design for an ongoing, Phase Ib/IIa, randomized, global, multi-center, double-blind, placebo-controlled, parallel-group study (Brainshuttle AD) investigating intravenous infusion of RG6102 in participants with prodromal or mild-to-moderate AD.  Brainshuttle AD will evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of RG6102.